China – based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) has announced its plan to subscribe to shares of Visen Pharmaceuticals via its initial public offering (IPO) on the Hong Kong Stock Exchange. Anhui Anke will invest up to USD31 million as a cornerstone investor.
About Visen Pharmaceuticals
Visen Pharmaceuticals is a China – based joint venture between Denmark – headquartered Ascendis Pharma and Chinese healthcare – focused investment firm Vivo Capital. It is a late – stage biopharmaceutical company with products nearing commercialization.
Product Pipeline
Visen Pharmaceuticals focuses on providing treatment options for specific endocrine disorders in China, including Hong Kong, Macau, and Taiwan. Its core product is TransCon hGH (lonapegsomatropin – tcgd), a weekly long – acting growth hormone replacement therapy. The company is also developing navepegritide, a long – acting C – type natriuretic peptide (CNP) prodrug for the treatment of cartilage dysplasia, and palopegteriparatide, a daily parathyroid hormone replacement therapy for chronic hypoparathyroidism.-Fineline Info & Tech
